Integrated Advisors Network LLC Lowers Stake in Johnson & Johnson (NYSE:JNJ)

Integrated Advisors Network LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 35,642 shares of the company’s stock after selling 1,854 shares during the period. Integrated Advisors Network LLC’s holdings in Johnson & Johnson were worth $5,306,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Hussman Strategic Advisors Inc. purchased a new position in Johnson & Johnson during the 3rd quarter worth $1,519,000. Heritage Wealth Advisors grew its position in Johnson & Johnson by 2.6% during the 3rd quarter. Heritage Wealth Advisors now owns 75,723 shares of the company’s stock worth $11,274,000 after purchasing an additional 1,908 shares during the last quarter. Illinois Municipal Retirement Fund grew its position in Johnson & Johnson by 379.7% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 46,929 shares of the company’s stock worth $6,987,000 after purchasing an additional 37,146 shares during the last quarter. CWH Capital Management Inc. grew its position in Johnson & Johnson by 2.5% during the 3rd quarter. CWH Capital Management Inc. now owns 18,694 shares of the company’s stock worth $2,783,000 after purchasing an additional 459 shares during the last quarter. Finally, LFA Lugano Financial Advisors SA purchased a new stake in shares of Johnson & Johnson in the third quarter valued at about $228,000. 67.44% of the stock is currently owned by institutional investors.

JNJ stock opened at $146.36 on Friday. The company has a market cap of $385.30 billion, a P/E ratio of 23.01, a P/E/G ratio of 3.04 and a beta of 0.69. Johnson & Johnson has a 52 week low of $109.16 and a 52 week high of $157.00. The company’s 50-day moving average price is $145.51 and its 200 day moving average price is $146.57. The company has a current ratio of 1.48, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.98 by $0.22. The company had revenue of $21.08 billion during the quarter, compared to analysts’ expectations of $20.15 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.12 earnings per share. On average, equities research analysts expect that Johnson & Johnson will post 7.99 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.01 per share. This represents a $4.04 dividend on an annualized basis and a yield of 2.76%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s payout ratio is currently 46.54%.

Several analysts have recently weighed in on the stock. Cantor Fitzgerald lifted their target price on shares of Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a report on Wednesday, October 14th. Stifel Nicolaus downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. Raymond James reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Friday. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. Finally, Credit Suisse Group lifted their target price on shares of Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a report on Wednesday, October 14th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $164.93.

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the transaction, the executive vice president now owns 66,658 shares in the company, valued at $10,233,336.16. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.27% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More: What is the Ex-Dividend Date in Investing?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.